NIH seeks to trim gene therapy review, turn oversight to newer tech

NIH wants to scrap Recombinant DNA Advisory Committee (RAC) review for gene therapy protocols in a move that will reduce redundant oversight while allowing RAC to

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE